Cipla Ltd has announced that the Company, in collaboration with the UK government, has expressed its intention to make investments of up to £100 million in its UK subsidiary over the next few years.
The investments are expected to facilitate the launch of a range of products in the area of respiratory, oncology and antiretroviral medicines to further Cipla’s higher purpose of "universal affordable access". Cipla also plans to invest in R&D activities, clinical trials and expand further internationally.
The investment underscores the growing importance of UK in Cipla’s long term strategy.
No comments:
Post a Comment